Seattle Children’s Reprogrammed T Cell Immunotherapy Clinical Trial Boasts 85% Complete Remission Rate in Children with Relapsed Leukemia 12.9.14 – Seattle Children’s Press Release Seattle Children’s announced today that 11 of 13 patients treated thus far in a clinical trial using genetically reprogrammed T cells to treat relapsed acute lymphoblastic leukemia (ALL) have achieved complete remission, confirmed by highly sensitive tests designed to detect minute amounts of cancer cells.
Families Find Hope in Success of Cancer Immunotherapy 12.9.14 – Seattle Children’s Press Release Researchers at Seattle Children’s are sharing their success thus far in treating leukemia using immunotherapy. While scientists are excited about progress of these clinical trials, no one is more grateful for this research than the families of the patients who have benefitted from it. Read the blog post to hear one family’s story.
Seattle Children’s Begins Enrolling Patients for Immunotherapy Research Trial for Neuroblastoma 11.6.14 – Seattle Children’s Press Release Seattle Children’s today announced the opening of patient enrollment for its new cellular immunotherapy clinical research trial designed to induce remission in children suffering from neuroblastoma, one of the deadliest forms of childhood cancer.
So much better, but still not enough – How we continue to improve cancer treatments 9.15.14 – Seattle Children’s Connection Magazine Clinical research has improved the outlook for most kids with cancer. Here’s why the future promises to be even better.
From hopeless to cancer-free: Young man saved with immunotherapy 2.18.14 – Seattle Children’s On the Pulse Five months ago, 20-year-old Milton Wright was given a death sentence. Today, he is expected to live a long, healthy life. This is the incredible story of how two determined researchers and the parents of a young boy came together to save him.
Seattle Children’s Research Institute partners in immunotherapy startup 12.5.13 – NPR/KUOW Radio Backed by $120 million in startup funding, Juno Therapeutics Inc. aims to develop immunotherapies that cure a wide range of cancers. Its founding partners are Seattle Children’s Research Institute, Fred Hutch and Memorial Sloan–Kettering Cancer Center.
Ben Towne Center awarded $1 million from the Life Sciences Discovery Fund 09.13.2013 – Seattle Children’s Press Release The Life Sciences Discovery Fund’s “Opportunity” grant will fuel studies of a cancer immunotherapy regimen that is in clinical trials. The grant is contingent upon Seattle Children’s Research Institute raising $1 million in matching funds.
Patient has positive response to new cancer treatment 07.10.2013 – KOMO News The first leukemia patient in the state to try a new cancer therapy is disease-free. The treatment, called cellular immunotherapy, is designed for the toughest cases of leukemia.
Dr. Michael Jensen named to research “dream team” 04.07.2013 – Press Release The innovative “dream team” project includes researchers from seven institutions, who will together receive $14.5 million to pursue novel therapies for the most challenging childhood cancers. The team was named by Stand up to Cancer, the St. Baldrick’s Foundation and their scientific partner, the American Association for Cancer Research.
Read more news about the Ben Towne Center